Alida Biosciences Company Profile

Background

Founded in 2020 and headquartered in San Diego, California, Alida Biosciences is a biotechnology company dedicated to advancing the field of epigenomics by developing accessible tools for epitranscriptomic research. The company's mission is to empower the evaluation of RNA code beyond its primary sequence, facilitating discoveries in diagnostics, therapeutics, and biotechnological applications. By leveraging expertise in protein engineering and enzymology, Alida Biosciences aims to position itself as a leader in the development of innovative epitranscriptomic tools.

Key Strategic Focus

Alida Biosciences focuses on creating cutting-edge tools that enable highly sensitive detection and quantification of RNA modifications through streamlined workflows and integrated bioinformatics pipelines. Their flagship product, the EpiPlex™ RNA Library Prep Kit, utilizes non-antibody binders (NABs) to facilitate multiplexed detection of RNA modifications such as 6-methyladenosine (m6A), 5-methylcytidine (m5C), pseudouridine, and inosine. This technology is particularly suited for analyzing input-limited clinical research RNA samples, addressing the limitations of traditional methods that require high RNA inputs and can only detect a single modification per assay.

Financials and Funding

In June 2024, Alida Biosciences completed a $7.5 million Series A funding round led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners. This funding is complemented by two ongoing Small Business Innovation Research (SBIR) grants totaling $4 million from the National Human Genome Research Institute (NHGRI). The capital is intended to accelerate product development and facilitate the broader distribution of the EpiPlex kit to researchers.

Pipeline Development

Alida Biosciences has launched two early-access products:

EpiPlex™ RNA Library Prep Kit: Designed for multiplexed detection of RNA modifications, enabling comprehensive epitranscriptomic analysis even from low RNA input samples.

EpiScout™ Analysis Suite: A bioinformatics platform that complements the EpiPlex kit by providing tools for analyzing and visualizing complex epitranscriptomic data, facilitating multiomics data integration.

These products aim to streamline workflows and enhance the sensitivity and accuracy of RNA modification detection, thereby advancing research in RNA biology.

Technological Platform and Innovation

Alida Biosciences' technological platform is distinguished by its use of non-antibody binders (NABs) in the EpiPlex kit, which offer high affinity and minimal off-target binding. This approach ensures superior reproducibility, sensitivity, and accuracy in detecting multiple RNA modifications simultaneously. The EpiPlex technology employs a proximity barcoding strategy, where fragmented RNA is mixed with beads containing distinct RNA modification barcodes and protein binders. Upon binding to target modifications, the barcodes are enzymatically transferred to the captured RNA, which is then prepared for sequencing. This method allows for the concurrent interrogation of multiple epitranscriptomic features in a single reaction.

Leadership Team

Gudrun Stengel, PhD: CEO & Co-Founder. Dr. Stengel has held leadership roles at Element Biosciences and Illumina, contributing to the development of sequencing platforms.

Byron Purse, PhD: Co-Founder. Dr. Purse is an organic chemistry professor at San Diego State University and has played a critical role in securing NIH funding for the company.

Andrew Price, PhD: Vice President, R&D.

Zachary Miles, PhD: Senior Director of Protein Engineering.

Eric Davis, PhD: Head of Software & Bioinformatics.

Nikita Warner, PhD: Senior Director of Product Management and Marketing.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within Alida Biosciences' leadership team.

Competitor Profile

Market Insights and Dynamics

The field of epitranscriptomics is rapidly evolving, with increasing recognition of RNA modifications' role in gene regulation and disease. The market for RNA analysis tools is expanding, driven by advancements in next-generation sequencing technologies and a growing emphasis on personalized medicine.

Competitor Analysis

While specific competitors are not detailed in the available information, companies developing RNA analysis tools and epigenomic research technologies represent the competitive landscape. Alida Biosciences differentiates itself through its innovative use of NABs and multiplexed detection capabilities, addressing limitations of traditional methods that require high RNA inputs and can only detect single modifications per assay.

Strategic Collaborations and Partnerships

In June 2025, Alida Biosciences announced its first service provider partnership with Baylor College of Medicine's GARP Core to offer multiplexed RNA modification sequencing. Additionally, in March 2025, the company collaborated with DNAnexus to enhance RNA modification and expression analysis.

Operational Insights

Alida Biosciences' strategic focus on developing user-friendly, highly sensitive RNA modification detection tools positions the company to address unmet needs in the research community. By offering solutions that require low RNA inputs and provide multiplexed detection, Alida Biosciences enhances its competitive advantage in the epitranscriptomics market.

Strategic Opportunities and Future Directions

The company's roadmap includes expanding its product offerings to cover additional RNA modifications and developing targeted analysis kits for specific diseases. Alida Biosciences also plans to explore applications in DNA modifications and histone modifications, aiming to link different epigenomic layers in a single assay. These initiatives align with the company's mission to broaden the application of epitranscriptomics in life sciences and personalized medicine.